<p>随着全球市场继续应对消费者通胀上升和企业盈利强劲的复杂局面，标准普尔 500 指数和纳斯达克综合指数等指数已达到新高，反映出投资者在经济信号混杂的情况下的信心。在这种环境下，内部持股比例高的成长型公司可能提供吸引人的投资机会，因为它们与股东利益的一致性可能在市场波动中提供韧性和持续表现的潜力。</p>
<h3>全球内部持股比例高的十大成长型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>上海华测导航技术 (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>老铺黄金 (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>金电路电子 (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>24.7%</td>
<td>94.8%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们快速增长的全球内部持股比例高的 814 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Alsea. de (BMV:ALSEA *)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Alsea, S.A.B. de C.V. 在拉丁美洲和欧洲经营餐厅，市值为 384.1 亿墨西哥比索。</p>
<p><strong>运营：</strong> Alsea 的收入来源包括来自拉丁美洲的食品和饮料销售 687.8 亿墨西哥比索，以及来自欧洲的 289.4 亿墨西哥比索的运营收入。</p>
<p><strong>内部持股比例：</strong> 38.9%</p>
<p><strong>盈利增长预测：</strong> 每年 26.1%。</p>
<p>Alsea, S.A.B. de C.V. 展现出作为一家成长型公司的潜力，内部持股比例显著，报告 2025 年第二季度盈利为 11.3 亿墨西哥比索，较去年 2820.3 万墨西哥比索大幅增长。其年利润增长预计将超过市场，达到 26.1%，尽管收入增长预计为每年 7.7% 的较温和水平。尽管交易价格略低于公允价值，并且预测的股本回报率较高，但它面临着利息覆盖和股价波动的挑战。</p>
<ul>
<li>点击这里访问我们的完整增长分析报告，以了解 Alsea. de 的动态。</li>
<li>我们编制的估值报告表明，Alsea. de 当前的价格可能相当适中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth"/></p>
<p>BMV:ALSEA * 截至 2025 年 7 月的盈利和收入增长</p>
<h2>爱博医疗科技 (北京) (SHSE:688050)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 爱博医疗科技（北京）有限公司专注于创新医疗解决方案，市值为 139.9 亿人民币。</p>
<p><strong>运营：</strong> 该公司主要通过其医疗产品部门产生收入，金额为 14.6 亿人民币。</p>
<p><strong>内部持股比例：</strong> 20.5%</p>
<p><strong>盈利增长预测：</strong> 每年 24.3%。</p>
<p>爱博医疗科技（北京）有望实现显著增长，预计收入和盈利每年增长超过 20%，超过中国市场平均水平。该公司的股票交易价格低于公允价值 23.5%，分析师预测价格将上涨 51.7%。最近的私募融资筹集了 2.8 亿人民币，表明强大的资本支持。然而，其股本回报率预计将保持在 18.3% 的低水平，最近没有报告显著的内部交易活动。</p>
<ul>
<li>点击这里深入了解爱博医疗科技（北京）的未来增长分析报告。</li>
<li>我们的综合估值报告提出，爱博医疗科技（北京）的价格可能低于其财务状况所能证明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown"/></p>
<p>SHSE:688050 截至 2025 年 7 月的持股结构</p>
<h2>Canmax Technologies (SZSE:300390)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Canmax Technologies Co., Ltd. 专注于提供新能源锂电池材料，市值为 167.5 亿人民币。</p>
<p><strong>运营：</strong> Canmax Technologies Co., Ltd. 主要通过提供新能源锂电池材料产生收入。</p>
<p><strong>内部持股比例：</strong> 33.7%</p>
<p><strong>盈利增长预测：</strong> 每年 43.8%。</p>
<p>Canmax Technologies 处于增长的有利位置，预计收入和盈利将显著快于中国市场平均水平。尽管前景积极，但该公司面临着预测的股本回报率低至 4.9% 和未能由盈利或自由现金流覆盖的不可持续股息的挑战。最近对其章程的修订可能表明战略转变，但最近几个月内部交易活动较少。</p>
<ul>
<li>通过阅读我们的分析师估计报告，深入了解 Canmax Technologies 的表现。</li>
<li>我们的 Canmax Technologies 估值报告中的分析表明，其股价可能高于其估计价值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown"/></p>
<p>SZSE:300390 截至 2025 年 7 月的持股结构</p>
<h2>将想法转化为行动</h2>
<ul>
<li>点击这里解锁我们 814 家快速增长的全球内部持股比例高的公司的完整列表。</li>
<li>对其他可能性感兴趣？最新的 GPU 需要一种名为铽的稀土金属，全球只有 25 家公司在探索或生产它。免费获取列表。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论仅基于历史数据和分析师预测，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

爱博医疗

零跑汽车

<p>随着全球市场面临消费者通胀上升和强劲的企业盈利，标普 500 指数和纳斯达克综合指数已达到新高。内部持股比例高的成长型公司呈现出吸引人的投资机会。值得注意的公司包括浙江零跑科技、KebNi 和 Alsea，这些公司都有显著的盈利增长预测。例如，Alsea 显示出 26.1% 的年利润增长，而爱博医疗科技预计增长超过 20%。尽管面临挑战，这些公司可能在波动的市场中提供韧性和持续表现的潜力</p>

<p>As global markets continue to navigate the complexities of rising consumer inflation and robust corporate earnings, indices such as the S&amp;P 500 and Nasdaq Composite have reached new highs, reflecting investor confidence amidst mixed economic signals. In this environment, growth companies with high insider ownership can offer appealing investment opportunities, as their alignment with shareholder interests may provide resilience and potential for sustained performance despite market fluctuations.</p>
<div class="lb-trans"><p>随着全球市场继续应对消费者通胀上升和企业盈利强劲的复杂局面，标准普尔 500 指数和纳斯达克综合指数等指数已达到新高，反映出投资者在经济信号混杂的情况下的信心。在这种环境下，内部持股比例高的成长型公司可能提供吸引人的投资机会，因为它们与股东利益的一致性可能在市场波动中提供韧性和持续表现的潜力。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球内部持股比例高的十大成长型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Zhejiang Leapmotor Technology (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>24.7%</td>
<td>94.8%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股比例</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>浙江零跑科技 (SEHK:9863)</td>
<td>15.6%</td>
<td>61%</td>
</tr>
<tr>
<td>上海华测导航技术 (SZSE:300627)</td>
<td>24.3%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Pharma Mar (BME:PHM)</td>
<td>11.8%</td>
<td>43.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>老铺黄金 (SEHK:6181)</td>
<td>35.5%</td>
<td>42.6%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>38.3%</td>
<td>94.5%</td>
</tr>
<tr>
<td>金电路电子 (TWSE:2368)</td>
<td>31.4%</td>
<td>25.9%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>13.6%</td>
<td>43.7%</td>
</tr>
<tr>
<td>Elliptic Laboratories (OB:ELABS)</td>
<td>24.4%</td>
<td>79%</td>
</tr>
<tr>
<td>Circus (XTRA:CA1)</td>
<td>24.7%</td>
<td>94.8%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 814 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们快速增长的全球内部持股比例高的 814 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Alsea. de (BMV:ALSEA *)</h2>
<div class="lb-trans"><h2>Alsea. de (BMV:ALSEA *)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Alsea, S.A.B. de C.V. operates restaurants across Latin America and Europe with a market cap of MX$38.41 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Alsea, S.A.B. de C.V. 在拉丁美洲和欧洲经营餐厅，市值为 384.1 亿墨西哥比索。</p>
</div><p><strong>Operations:</strong> Revenue segments for Alsea include MX$68.78 billion from food and beverage sales in Latin America and MX$28.94 billion from operations in Europe.</p>
<div class="lb-trans"><p><strong>运营：</strong> Alsea 的收入来源包括来自拉丁美洲的食品和饮料销售 687.8 亿墨西哥比索，以及来自欧洲的 289.4 亿墨西哥比索的运营收入。</p>
</div><p><strong>Insider Ownership:</strong> 38.9%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 38.9%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 26.1% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 26.1%。</p>
</div><p>Alsea, S.A.B. de C.V. demonstrates potential as a growth company with significant insider ownership, reporting strong Q2 2025 earnings of MXN 1.13 billion, up from MXN 282.03 million the previous year. Its annual profit growth is expected to outpace the market at 26.1%, though revenue growth is projected at a more moderate rate of 7.7% annually. Despite trading slightly below fair value and having high forecasted return on equity, it faces challenges with interest coverage and share price volatility.</p>
<div class="lb-trans"><p>Alsea, S.A.B. de C.V. 展现出作为一家成长型公司的潜力，内部持股比例显著，报告 2025 年第二季度盈利为 11.3 亿墨西哥比索，较去年 2820.3 万墨西哥比索大幅增长。其年利润增长预计将超过市场，达到 26.1%，尽管收入增长预计为每年 7.7% 的较温和水平。尽管交易价格略低于公允价值，并且预测的股本回报率较高，但它面临着利息覆盖和股价波动的挑战。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Alsea. de.</li>
<li>The valuation report we've compiled suggests that Alsea. de's current price could be quite moderate.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整增长分析报告，以了解 Alsea. de 的动态。</li>
<li>我们编制的估值报告表明，Alsea. de 当前的价格可能相当适中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/810e87af-2a79-4c5e-bbe6-cdbe5b7dda0e/chart/earnings-and-revenue-growth"/></p>
<p>BMV:ALSEA * Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>BMV:ALSEA * 截至 2025 年 7 月的盈利和收入增长</p>
</div><h2>Eyebright Medical Technology (Beijing) (SHSE:688050)</h2>
<div class="lb-trans"><h2>爱博医疗科技 (北京) (SHSE:688050)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Eyebright Medical Technology (Beijing) Co., Ltd. operates in the medical technology sector, focusing on innovative healthcare solutions, with a market cap of CN¥13.99 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 爱博医疗科技（北京）有限公司专注于创新医疗解决方案，市值为 139.9 亿人民币。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its medical products segment, amounting to CN¥1.46 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其医疗产品部门产生收入，金额为 14.6 亿人民币。</p>
</div><p><strong>Insider Ownership:</strong> 20.5%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 20.5%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 24.3% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 24.3%。</p>
</div><p>Eyebright Medical Technology (Beijing) is poised for substantial growth, with revenue and earnings forecasted to expand over 20% annually, surpassing the Chinese market averages. The company's shares are trading at 23.5% below fair value, with analysts predicting a 51.7% price increase. Recent private placements raised CNY 280 million, indicating strong capital backing. However, its return on equity is expected to remain low at 18.3%, and no significant insider trading activity has been reported recently.</p>
<div class="lb-trans"><p>爱博医疗科技（北京）有望实现显著增长，预计收入和盈利每年增长超过 20%，超过中国市场平均水平。该公司的股票交易价格低于公允价值 23.5%，分析师预测价格将上涨 51.7%。最近的私募融资筹集了 2.8 亿人民币，表明强大的资本支持。然而，其股本回报率预计将保持在 18.3% 的低水平，最近没有报告显著的内部交易活动。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Eyebright Medical Technology (Beijing).</li>
<li>Our comprehensive valuation report raises the possibility that Eyebright Medical Technology (Beijing) is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解爱博医疗科技（北京）的未来增长分析报告。</li>
<li>我们的综合估值报告提出，爱博医疗科技（北京）的价格可能低于其财务状况所能证明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/ownership-breakdown"/></p>
<p>SHSE:688050 Ownership Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>SHSE:688050 截至 2025 年 7 月的持股结构</p>
</div><h2>Canmax Technologies (SZSE:300390)</h2>
<div class="lb-trans"><h2>Canmax Technologies (SZSE:300390)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Canmax Technologies Co., Ltd. specializes in providing new energy lithium battery materials and has a market cap of CN¥16.75 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Canmax Technologies Co., Ltd. 专注于提供新能源锂电池材料，市值为 167.5 亿人民币。</p>
</div><p><strong>Operations:</strong> Canmax Technologies Co., Ltd. generates its revenue primarily from the provision of new energy lithium battery materials.</p>
<div class="lb-trans"><p><strong>运营：</strong> Canmax Technologies Co., Ltd. 主要通过提供新能源锂电池材料产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 33.7%</p>
<div class="lb-trans"><p><strong>内部持股比例：</strong> 33.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 43.8% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 43.8%。</p>
</div><p>Canmax Technologies is positioned for growth, with revenue and earnings expected to grow significantly faster than the Chinese market averages. Despite this positive outlook, the company faces challenges with low forecasted return on equity at 4.9% and unsustainable dividends not covered by earnings or free cash flows. Recent amendments to its articles of association may indicate strategic shifts, but insider trading activity has been minimal in recent months.</p>
<div class="lb-trans"><p>Canmax Technologies 处于增长的有利位置，预计收入和盈利将显著快于中国市场平均水平。尽管前景积极，但该公司面临着预测的股本回报率低至 4.9% 和未能由盈利或自由现金流覆盖的不可持续股息的挑战。最近对其章程的修订可能表明战略转变，但最近几个月内部交易活动较少。</p>
</div><ul>
<li>Get an in-depth perspective on Canmax Technologies' performance by reading our analyst estimates report here.</li>
<li>The analysis detailed in our Canmax Technologies valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的分析师估计报告，深入了解 Canmax Technologies 的表现。</li>
<li>我们的 Canmax Technologies 估值报告中的分析表明，其股价可能高于其估计价值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/97f013da-1b1b-41ea-9cd4-1b7a19746e9c/chart/ownership-breakdown"/></p>
<p>SZSE:300390 Ownership Breakdown as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:300390 截至 2025 年 7 月的持股结构</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>将想法转化为行动</h2>
</div><ul>
<li>Unlock our comprehensive list of 814 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Interested In Other Possibilities? The latest GPUs need a type of rare earth metal called Terbium and there are only 25 companies in the world exploring or producing it. Find the list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里解锁我们 814 家快速增长的全球内部持股比例高的公司的完整列表。</li>
<li>对其他可能性感兴趣？最新的 GPU 需要一种名为铽的稀土金属，全球只有 25 家公司在探索或生产它。免费获取列表。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论仅基于历史数据和分析师预测，采用无偏见的方法，我们的文章并不意图提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有预测的收入和收益增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

2025 年 7 月全球增长型公司及其高内部持股情况